Recombinant Human Flt-3 Ligand/FLT3L Protein

Images

 
1 µg/lane of Recombinant Human Flt-3 Ligand/FLT3L was resolved with SDS-PAGE under reducing (R) conditions and visualized by silver staining, showing major bands at 22‑26 kDa. The multiple bands are due to variable ...read more
Recombinant Human Flt-3 Ligand/FLT3L (Catalog # 308-FK) stimulates cell proliferation in the BaF3 mouse pro-B cell line transfected with mouse Flt-3. The ED50 for this effect is 0.2-1 ng/mL.

Product Details

Summary
Reactivity HuSpecies Glossary
Applications Bioactivity

Order Details

Recombinant Human Flt-3 Ligand/FLT3L Protein Summary

Details of Functionality
Measured in a cell proliferation assay using BaF3 mouse pro‑B cells transfected with mouse Flt-3. The ED50 for this effect is 0.2-1 ng/mL.
The specific activity of Recombinant Human Flt-3 Ligand/FLT3L is approximately 1.2 x 103 U/μg, which is calibrated against Recombinant Human Flt-3 Ligand/FLT3L WHO Standard (NIBSC code: 96/532).
Source
Spodoptera frugiperda, Sf 21 (baculovirus)-derived human Flt-3 Ligand/FLT3L protein
Thr27-Pro185
Accession #
N-terminal Sequence
Thr27
Protein/Peptide Type
Recombinant Proteins
Gene
FLT3LG
Purity
>97%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Endotoxin Note
<0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

Theoretical MW
17.5 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
SDS-PAGE
17-30 kDa, reducing conditions
Publications
Read Publications using
308-FK in the following applications:

Packaging, Storage & Formulations

Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Buffer
Lyophilized from a 0.2 μm filtered solution in Acetonitrile and TFA with BSA as a carrier protein.
Purity
>97%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Reconstitution Instructions
Reconstitute at 100 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human Flt-3 Ligand/FLT3L Protein

  • FL
  • FLG3L
  • Flt3 ligand
  • Flt-3 Ligand
  • Flt3L
  • FLT3LG
  • fms-related tyrosine kinase 3 ligand
  • SL cytokine

Background

Flt‑3 Ligand, also known as FLT3L, is an alpha-helical cytokine that promotes the differentiation of multiple hematopoietic cell lineages (1-3). Mature human Flt‑3 Ligand consists of a 158 amino acid (aa) extracellular domain (ECD) with a cytokine-like domain and a juxtamembrane tether region, a 21 aa transmembrane segment, and a 30 aa cytoplasmic tail (4-7). Within the ECD, human Flt‑3 Ligand shares 71% and 65% aa sequence identity with mouse and rat Flt‑3 Ligand, respectively (4-6). The human and mouse Flt‑3 Ligand proteins show cross-species activity. Flt-3 Ligand is also structurally related to M-CSF and SCF. Flt-3 Ligand is widely expressed in various human and mouse tissues. It is expressed as a noncovalently-linked dimer by T cells and bone marrow and thymic fibroblasts (1, 8). Each 36 kDa chain of the Flt-3 Ligand dimer carries approximately 12 kDa of N- and O-linked carbohydrates (8). Alternate splicing and proteolytic cleavage of the transmembrane form of the Flt-3 Ligand protein can generate a soluble 30 kDa fragment that includes the cytokine-like domain (4, 8). Alternate splicing of human Flt‑3 Ligand also generates membrane-associated isoforms that contain either a truncated cytoplasmic tail or an 85 aa substitution following the cytokine-like domain in the ECD of the Flt-3 Ligand protein (4, 5, 8). Both transmembrane and soluble forms of Flt‑3 Ligand signal through the tyrosine kinase receptor Flt-3/Flk-2 (3, 4, 6, 7). Flt‑3 Ligand induces the expansion of monocytes and immature dendritic cells as well as early B cell lineage differentiation (2, 9). Additionally, Flt-3 Ligand synergizes with IL-3, GM-CSF, and SCF to promote the mobilization and myeloid differentiation of hematopoietic stem cells (4-6). Flt-3 Ligand also cooperates with IL-2, IL-6, IL-7, and IL-15 to induce NK cell development and with IL-3, IL-7, and IL-11 to induce terminal B cell maturation (1, 10). Animal studies show that Flt‑3 Ligand reduces the severity of experimentally induced allergic inflammation (11).
  1. Wodnar-Filipowicz, A. (2003) News Physiol. Sci. 18:247.
  2. Dong, J. et al. (2002) Cancer Biol. Ther. 1:486.
  3. Gilliland, D.G. and J.D. Griffin (2002) Blood 100:1532.
  4. Hannum, C. et al. (1994) Nature 368:643.
  5. Lyman, S.D. et al. (1994) Blood 83:2795.
  6. Lyman, S.D. et al. (1993) Cell 75:1157.
  7. Savvides, S.N. et al. (2000) Nat. Struct. Biol. 7:486.
  8. McClanahan, T. et al. (1996) Blood 88:3371.
  9. Diener, K.R. et al. (2008) Exp. Hematol. 36:51.
  10. Farag, S.S. and M.A. Caligiuri (2006) Blood Rev. 20:123.
  11. Edwan, J.H. et al. (2004) J. Immunol. 172:5016.

Customers Who Viewed This Item Also Viewed...

NBP2-42210
Species: Hu
Applications: WB, Flow, IHC, IHC-P
NB600-1071
Species: Mu, Rt
Applications: WB, ELISA, Flow, ICC/IF, IHC, IHC-Fr, IHC-P, IP
7270-IL/CF
Species: Hu
NBP1-92684
Species: Hu, Mu, Rt, Po, Bv, Eq
Applications: WB, ICC/IF, IHC
7954-GM/CF
Species: Hu
7954-GM/CF
Species: Hu
NBP1-97765
Species: Hu
Applications: WB, IHC, IHC-P, PEP-ELISA
NBP2-79843
Species: Hu
Applications: WB, ELISA, Flow, ICC/IF, IHC, IHC-P, PA, CyTOF-ready
NB100-524
Species: Hu, Mu
Applications: WB, Flow, ICC/IF, IHC, IHC-Fr, IHC-P, IP, Flow-IC
NBP1-49045
Species: Mu, Rt
Applications: Flow, ICC/IF, IHC, IHC-Fr, IHC-P, IP, Cell Depl, CyTOF-ready, InhibTFunc

Publications for Flt-3 Ligand/FLT3L (308-FK)(50)

We have publications tested in 6 confirmed species: Human, Mouse, Primate - Callitrix jacchus (Common Marmoset), Primate - Macaca fascicularis (Crab-eating Monkey or Cynomolgus Macaque), Primate - Macaca mulatta (Rhesus Macaque), Primate - Papio anubis (Olive Baboon).

We have publications tested in 2 applications: Bioassay, Cell Culture.


Filter By Application
Bioassay
(41)
Cell Culture
(7)
All Applications
Filter By Species
Human
(38)
Mouse
(5)
Primate - Callitrix jacchus (Common Marmoset)
(1)
Primate - Macaca fascicularis (Crab-eating Monkey or Cynomolgus Macaque)
(1)
Primate - Macaca mulatta (Rhesus Macaque)
(2)
Primate - Papio anubis (Olive Baboon)
(1)
All Species
Showing Publications 1 - 10 of 50. Show All 50 Publications.
Publications using 308-FK Applications Species
A Leonard, M Yapundich, T Nassehi, J Gamer, CM Drysdale, JJ Haro-Mora, S Demirci, MM Hsieh, N Uchida, JF Tisdale Low-Dose Busulfan Reduces Human CD34+ Cell Doses Required for Engraftment in c-kit Mutant Immunodeficient Mice Mol Ther Methods Clin Dev, 2019;15(0):430-437. 2019 [PMID: 31890735] (Bioassay, Human) Bioassay Human
S Charrier, C Lagresle-P, V Poletti, M Rothe, G Cédrone, B Gjata, F Mavilio, A Fischer, A Schambach, JP de Villart, M Cavazzana, S Hacein-Bey, A Galy Biosafety Studies of a Clinically Applicable Lentiviral Vector for the Gene Therapy of Artemis-SCID Mol Ther Methods Clin Dev, 2019;15(0):232-245. 2019 [PMID: 31720302] (Cell Culture, Mouse) Cell Culture Mouse
J Grajcarek, J Monlong, Y Nishinaka-, M Nakamura, M Nagai, S Matsuo, D Lougheed, H Sakurai, MK Saito, G Bourque, K Woltjen Genome-wide microhomologies enable precise template-free editing of biologically relevant deletion mutations Nat Commun, 2019;10(1):4856. 2019 [PMID: 31649251] (Bioassay, Human) Bioassay Human
N Uchida, MM Hsieh, L Raines, JJ Haro-Mora, S Demirci, AC Bonifacino, AE Krouse, ME Metzger, RE Donahue, JF Tisdale Development of a forward-oriented therapeutic lentiviral vector for hemoglobin disorders Nat Commun, 2019;10(1):4479. 2019 [PMID: 31578323] (Cell Culture, Human) Cell Culture Human
GL Rogers, HY Chen, H Morales, PM Cannon Homologous Recombination-Based Genome Editing by Clade F AAVs Is Inefficient in the Absence of a Targeted DNA Break Mol. Ther., 2019;27(10):1726-1736. 2019 [PMID: 31540849] (Bioassay, Human) Bioassay Human
M Ly, S Rentas, A Vujovic, N Wong, S Moreira, J Xu, N Holzapfel, S Bhatia, D Tran, MD Minden, JS Draper, KJ Hope Diminished AHR signaling drives human acute myeloid leukemia stem cell maintenance Cancer Res., 2019;0(0):. 2019 [PMID: 31519687] (Bioassay, Human) Bioassay Human
MD McKenzie, M Ghisi, EP Oxley, S Ngo, L Cimmino, C Esnault, R Liu, JM Salmon, CC Bell, N Ahmed, M Erlichster, MT Witkowski, GJ Liu, M Chopin, A Dakic, E Simankowic, G Pomilio, T Vu, P Krsmanovic, S Su, L Tian, TM Baldwin, DA Zalcenstei, L DiRago, S Wang, D Metcalf, RW Johnstone, BA Croker, GI Lancaster, AJ Murphy, SH Naik, SL Nutt, V Pospisil, T Schroeder, M Wall, MA Dawson, AH Wei, H de Thé, ME Ritchie, J Zuber, RA Dickins Interconversion between Tumorigenic and Differentiated States in Acute Myeloid Leukemia Cell Stem Cell, 2019;25(2):258-272.e9. 2019 [PMID: 31374198] (Cell Culture, Human) Cell Culture Human
M Nasri, M Ritter, P Mir, B Dannenmann, N Aghaallaei, D Amend, V Makaryan, Y Xu, B Fletcher, R Bernhard, I Steiert, K Hahnel, J Berger, I Koch, B Sailer, K Hipp, C Zeidler, M Klimiankou, B Bajoghli, DC Dale, K Welte, J Skokowa CRISPR/Cas9 mediated ELANE knockout enables neutrophilic maturation of primary hematopoietic stem and progenitor cells and induced pluripotent stem cells of severe congenital neutropenia patients Haematologica, 2019;0(0):. 2019 [PMID: 31248972] (Bioassay, Human) Bioassay Human
M Ruiz-Gutie, ÖV Bölükba??, G Alexe, AG Kotini, K Ballotti, CE Joyce, DW Russell, K Stegmaier, K Myers, CD Novina, EP Papapetrou, A Shimamura Therapeutic discovery for marrow failure with MDS predisposition using pluripotent stem cells JCI Insight, 2019;5(0):. 2019 [PMID: 31039138] (Cell Culture, Human) Cell Culture Human
M Suga, T Kondo, K Imamura, R Shibukawa, Y Okanishi, Y Sagara, K Tsukita, T Enami, M Furujo, K Saijo, Y Nakamura, M Osawa, MK Saito, S Yamanaka, H Inoue Generation of a human induced pluripotent stem cell line, BRCi001-A, derived from a patient with mucopolysaccharidosis type I Stem Cell Res, 2019;36(0):101406. 2019 [PMID: 30849633] (Bioassay, Human) Bioassay Human
Show All 50 Publications.

Reviews for Flt-3 Ligand/FLT3L (308-FK) (0)

There are no reviews for Flt-3 Ligand/FLT3L (308-FK). By submitting a review you will receive an Amazon e-Gift Card or Novus Product Discount.
  • Review with no image -- $10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen
  • Review with an image -- $25/€18/£15/$25 CAD/¥150 Yuan/¥2500 Yen

FAQs for Flt-3 Ligand/FLT3L (308-FK) (0)

There are no specific FAQs related to this product. Read our general customer & technical service FAQs.

Other Available Formats

Additional Flt-3 Ligand/FLT3L Products

Bioinformatics Tool for Flt-3 Ligand/FLT3L (308-FK)

Discover related pathways, diseases and genes to Flt-3 Ligand/FLT3L (308-FK). Need help? Read the Bioinformatics Tool Guide for instructions on using this tool.
Visit Tool

Diseases for Flt-3 Ligand/FLT3L (308-FK)

Discover more about diseases related to Flt-3 Ligand/FLT3L (308-FK).
 

Pathways for Flt-3 Ligand/FLT3L (308-FK)

View related products by pathway.

PTMs for Flt-3 Ligand/FLT3L (308-FK)

Learn more about PTMs related to Flt-3 Ligand/FLT3L (308-FK).

Blogs on Flt-3 Ligand/FLT3L

There are no specific blogs for Flt-3 Ligand/FLT3L, but you can read our latest blog posts.
Recombinant Monoclonal Antibodies

Customers Who Bought This Also Bought

Contact Information

Product PDFs

Calculators

Concentration Calculator

The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.

=
÷

Review this Product

Be the first to review our Recombinant Human Flt-3 Ligand/FLT3L Protein and receive a gift card or discount.

Bioinformatics

Gene Symbol FLT3LG
Uniprot